COVID-19 presents a broad range of symptoms, varying in intensity from mild to severe and even life-threatening.

Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases.

A large interdisciplinary team of researchers has found that as mice age, levels of a certain type of immunoglobulin escalate ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

The team noted that the antibody selectively targets cells with elevated CD84 levels, sparing healthy immune cells, which ...

New research from Emory University reveals that nasal autoantibodies in COVID-19 patients may help predict disease severity, ...

An antibody treatment that blocks the building ... creating an intercellular bridge. In the type of blood cancer studied, CD84 is expressed in high quantities on the cancerous cells themselves ...

New research from Emory University is providing a more precise prediction of COVID-19 severity that can be found by looking ...

Researchers suggest that this treatment approach could be applied to various cancer types by focusing on the tumour ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

It provides a more precise prediction than currently available of how serious the case is by focusing on autoantibodies in ...